ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer by García-Escolano, Marta et al.
cancers
Article
ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor
Outcome in Immunophenotypes of Breast Cancer
Marta Garcia-Escolano 1,* , Yoel G. Montoyo-Pujol 1 , Fernando Ortiz-Martinez 1, Jose J. Ponce 2,
Silvia Delgado-Garcia 3, Tina A. Martin 3, Hortensia Ballester 3 , F. Ignacio Aranda 4, Elena Castellon-Molla 4,





F.; Ponce, J.J.; Delgado-Garcia, S.;
Martin, T.A.; Ballester, H.; Aranda,
F.I.; Castellon-Molla, E.;
Sempere-Ortells, J.M.; et al. ID1 and
ID4 Are Biomarkers of Tumor
Aggressiveness and Poor Outcome in
Immunophenotypes of Breast Cancer.




Received: 29 December 2020
Accepted: 24 January 2021
Published: 27 January 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Research Department, University General Hospital of Alicante, and Alicante Institute for Health and
Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain; montoyo_yoe@gva.es (Y.G.M.-P.);
fernando.ortiz@qiagen.com (F.O.-M.); peiro_glo@gva.es (G.P.)
2 Medical Oncology Department, University General Hospital of Alicante, and Alicante Institute for Health
and Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain; ponce_joslor@gva.es
3 Gynecology and Obstetrics Department, University General Hospital of Alicante, and Alicante Institute for
Health and Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain;
delgado_sil@gva.es (S.D.-G.); martin_tin@gva.es (T.A.M.); ballester_hor@gva.es (H.B.)
4 Pathology Department, University General Hospital of Alicante, and Alicante Institute for Health and
Biomedical Research (ISABIAL), Pintor Baeza 12, 03010 Alicante, Spain; aranda_ign@gva.es (F.I.A.);
castellon_ele@gva.es (E.C.-M.)
5 Biotechnology Department, Immunology Division, University of Alicante, Ctra San Vicente s/n. 03080-San
Vicente del Raspeig, 03010 Alicante, Spain; josemiguel@ua.es
* Correspondence: garcia_marescd@gva.es; Tel.: +34-965-913953 (ext. 3952)
Simple Summary: Inhibitor of differentiation (ID) proteins are essential to promote proliferation
during embryonic development, but they are silenced in most adult tissues. Evidence to date shows
ID1 expression in many tumor types, including breast cancer. However, the role of the remaining ID
family members, especially ID4, in breast cancer remains unclear. In this work, we aimed to assess
the four ID genes expression in breast cancer cell lines and a long series of breast cancer samples and
correlate them with clinicopathological features and patients’ survival. We observed a significantly
higher expression of ID4 in tumor cell lines than the healthy breast epithelium cell line. We confirmed
that the overexpression of ID1 and ID4 correlated with more aggressive phenotypes and poor survival
in breast cancer patients’ samples. Our results support the importance of ID proteins as targets for
the development of anti-cancer drugs.
Abstract: Inhibitor of differentiation (ID) proteins are a family of transcription factors that contribute
to maintaining proliferation during embryogenesis as they avoid cell differentiation. Afterward,
their expression is mainly silenced, but their reactivation and contribution to tumor development
have been suggested. In breast cancer (BC), the overexpression of ID1 has been previously described.
However, whether the remaining ID genes have a specific role in this neoplasia is still unclear.
We studied the mRNA expression of all ID genes by q RT-PCR in BC cell lines and 307 breast
carcinomas, including all BC subtypes. Our results showed that ID genes are highly expressed
in all cell lines tested. However, ID4 presented higher expression in BC cell lines compared to a
healthy breast epithelium cell line. In accordance, ID1 and ID4 were predominantly overexpressed in
Triple-Negative and HER2-enriched samples. Moreover, high levels of both genes were associated
with larger tumor size, histological grade 3, necrosis and vascular invasion, and poorer patients’
outcomes. In conclusion, ID1 and ID4 may act as biomarkers of tumor aggressiveness and worse
prognosis in breast cancer, and they could be used as potential targets for new treatments discover.
Keywords: inhibitor of differentiation (ID); mRNA expression; breast carcinoma; immunopheno-
type; prognosis
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1. Introduction
Breast cancer (BC) is the most common cancer diagnosed among women and is still the
leading cause of cancer-related death in this gender worldwide [1]. In the last decades, we
have witnessed the appearance of new diagnosis methods that have increased the diagnosis
of early stages of BC [2]. This fact, added to the implementation of novel therapies [3],
has improved BC patients’ prognosis. Indeed, the current 5-year survival rate is 91.1% [4].
Despite these advances, about 30% of BC patients relapse [5]. Additionally, the 5-year
survival rate decreases dramatically to 27% for patients diagnosed with advanced stages
of the disease [6], and there are still no specific treatments for the triple-negative breast
cancer (TNBC) subtype [7]. These data bring to light the need for finding new targets for
the efficient treatment of the most aggressive breast tumors.
The inhibitor of differentiation (ID) proteins are a family of four (ID1-4) helix-loop-
helix (HLH) transcription factors that lack the DNA binding domain. They act by recruiting
other transcription regulators forming homo- or hetero-dimers that fail to bind the E-
sequences of DNA. As a result, the transcription of E-box dependent genes is inhibited [8].
IDs sequence and structure are very conserved among family members and species, espe-
cially the HLH domain, indicating that they exert an important function [9,10]. In fact, ID
proteins play a crucial role during development, where they regulate cell fate by impairing
senescence [11]. Despite this, the ID expression patterns usually overlap, and it is known
that they are differentially regulated, which suggests different functions for each of them.
In adulthood, their expression is mainly restricted to some populations of stem cells [12–14]
or tissues that proliferate as an injury response [15].
The activation and participation of the ID family, especially ID1, in tumor development
have been widely studied in several tumor types. For instance, the expression of ID1 has
generally been associated with malignant behavior and poorer prognosis in the stomach,
colon, prostate, ovary, bladder, pancreas, and brain tumors, among others (reviewed in [16]).
In contrast, in other cancer types such as hepatic or thyroid tumors, the role of ID1 is not so
evident [17–20]. In BC, most of the studies carried out included a short clinical series or
experimental cell models. Data reported have associated ID1 with hormone receptors (HR)
negative status, aggressive phenotypes, and shorter survival [21–24]. Nevertheless, some
authors have obtained different results [25].
In contrast to ID1, little data are available about the contribution of the other ID pro-
teins to tumor malignancy. Previous investigators have demonstrated an association of ID2
expression with tumor development, aggressiveness, and chemotherapy resistance [26–28].
However, in BC, there is also evidence supporting the opposite role [29]. Similarly, recent
studies postulate that ID3 expression may contribute to chemo-resistance [30,31], while
others claim that it may reverse multi-drug resistance and increase chemosensitivity [32,33].
It is interesting to highlight the controversy surrounding ID4. It is the longest protein
of this family [34], and it shows expression patterns that differ from the other three family
members [10,35]. In fact, ID4 has been proposed as a regulatory factor of the expression
of the remaining ID proteins [36]. Increased expression of ID4 has been observed in some
tumor types such as hepatocellular carcinoma [37], glioblastoma [38], or melanoma [39],
indicating a possible role in tumor development. On the contrary, other authors have
reported that loss of ID4 by hypermethylation increases tumor progression and metasta-
sis [40,41], supporting the theory of ID4 being a tumor suppressor gene. In BC, the interest
in ID4 has generally been focused on another direction. It is known that, in the breast,
there is a negative regulation loop between ID4 and BRCA1 [42], and most of the studies
published to date investigate the dysregulation of this loop during BC development [43].
Here, we aimed to assess the contribution of ID genes in BC malignancy and clarify
the dual role of ID4 in this neoplasia. To that end, we analyzed the expression of the four
ID genes in BC cell lines and a large clinical series of BC patients, previously stratified by
immunophenotypes. mRNA expression results were correlated with clinicopathological
parameters and patients’ outcome. We found that ID4 presented high mRNA expression in
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BC cell lines. Moreover, in the analyzed clinical series, its overexpression, together with
ID1, was associated with aggressive clinic-pathological factors and poor survival.
2. Results
2.1. ID Genes Expression in BC Cell Lines
We detected high mRNA expression of the four ID genes in all cell lines, including the
non-tumor cell line 184A1, which indeed showed significantly higher expression of ID1 and
ID3 than all the tumor cell lines (all p ≤ 0.03). When we excluded 184A1 from the analysis,
MCF-7 showed the highest levels of ID1 compared with the other cell lines (all p ≤ 0.03).
In contrast, ID3 levels did not differ significantly among tumor cell lines. All cell lines
showed a similar expression of ID2, except MDA-MB-231, which showed no expression.
Regarding ID4, all tumor cell lines showed increased expression compared with 184A1 (all
p ≤ 0.06), meaning that this gene could have a specific role in BC pathogenesis. Among the
tumor cell lines, MCF-7 presented the highest levels of ID4 expression (Figure 1).
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Figure 1. mRNA expression of ID genes (A: ID1, B: ID2; C: ID3; D: ID4) in six breast tumor cell lines (MCF-7, T47-D, BT-
474, SK-BR-3, MDA-MB-231, and MDA-MB-468) and the breast epithelium cell line 184A1. All experiments were done 
three times. Each graph shows the average and standard derivation (error bars) of the three measurements. * p < 0.05 
compared to all the other cell lines. 
Figure 1. Cont.
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Figure 1. mRNA expression of ID genes (A: ID1, B: ID2; C: ID3; D: ID4) in six breast tumor cell lines (MCF-7, T47-D, BT-474,
SK-BR-3, MDA-MB-231, and MDA-MB-468) and the breast epithelium cell line 184A1. All experiments were done three
times. Each graph shows the average and standard derivation (error bars) of the three measurements. * p < 0.05 compared
to ll the other cell lines.
2.2. Patients’ and Tumor Characteristics
In our clinical series of 307 non-consecutive patients with breast carcinoma, the mean
age at diagnosis was 55.3 years (range 23–88). Tumors were predominantly larger than
20 mm (54.9%), with histological grade 3 (59.9%), absence of necrosis (65.1%) or vascular
invasion (63.3%), and negative lymph nodes (61.2%). We classified samples into five molec-
ular subtypes according to a validated IHC surrogate profile panel [44] as follows: 19.9%
luminal A-like, 19.2% luminal B/HER2-negative, 15.6% luminal B/HER2-positive, 13.4%
HER2-enriched, and 31.9% TNBC. All patients had a follow-up (FU) at least 12 months,
being the median FU 62 months (P25 = 40 months; P75 =113 months). The median OS was
62 months (range 2–295 months), whereas the median period to local recurrence or distant
metastasis was 45 months (range 2–214 months).
2.3. ID Genes Are Overexpressed in Most Analyzed Tumor Samples
As for the study exclusion criteria, we did not analyze ID genes’ expression in 10
samples. The remaining 297 samples were classified according to the expression of ID genes
into two groups: overexpression (FC ≥ 2) and normal-low expression (FC < 2). Based on
this, ID1 was overexpressed in 61 samples (20.5%), ID2 in 83 (27.9%), ID3 in 61 (20.5%), and
ID4 in 49 (16.5%). When considering the ID family together, 50.5% of the studied tumors
presented overexpression of at least one ID gene (Figure 2). Regarding these samples,
52.0% had only one ID gene overexpressed, whereas overexpression of the four ID genes
simultaneously was found in 6.0% of them.
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Figure 2. Heat map representing the expression of ID genes in all BC samples (n = 307) according to BC phenotypes.
Normal–low expression (FC < 2) is represented in blue and overexpression (FC ≥ 2) is represented in red. Samples with no
available data (n = 10) are colored gray.
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2.4. ID1 and ID4 Overexpression Is Associated with Aggressive Clinicopathological Features
We found ID1 and ID4 overexpression in tumors larger than 20 mm (68.3%, p = 0.012;
and 67.3%, p = 0.036, respectively), with histological grade 3 (78.7%, p = 0.029; and 79.6%,
p = 0.042, respectively), and necrosis (50.0% p = 0.003; and 52.1% p = 0.004, respectively).
Additionally, the overexpression of ID4 was associated with the presence of vascular
invasion (51.0%, p = 0.015) but as a trend for ID1 overexpression (45.9%, p = 0.055). Despite
most of the samples with high expression of ID4 were from patients older than 50 (73.5%),
this association was marginally significant (p = 0.071). All data shown in Table 1.
A trend towards significance was observed between ID2 overexpression and necrosis
(72.3%, p = 0.091). No significant associations were found for ID3 (Table S1).
Regarding the intrinsic BC subtypes, ID1 and ID4 were predominantly overexpressed
in the aggressive subtypes TNBC and HER2-enriched (p = 0.020 and p = 0.041, respectively)
(Figure 3). In contrast, ID2 and ID3 overexpression were more frequently found in luminal B
subtypes, although differences among phenotypes were not significant (p > 0.05) (Figure S1).
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2.5. Patients Expressing High Levels of ID1 and ID4 Present Shorter OS and DFS
Univariate analyses (Table 2) revealed that patients with larger tumor size (HR: 2.8;
95% CI = 1.5, 5.2; p = 0.002), histological grade 3 (HR: 8.1; 95% CI = 1.1, 58.8; p = 0.040),
necrosis (HR: 1.8; 95% CI = 1.0, 3.2; p = 0.042), vascular invasion (HR: 2.6; 95% CI = 1.4, 4.6;
p = 0.001), positive lymph-nodes (HR: 2.6; 95% CI = 1.4, 4.6; p = 0.001), absence of hormone
receptors (HR: 1.8; 95% CI = 1.0, 3.3; p = 0.039) and ID4 overexpression (HR: 2.1; 95% CI =
1.2, 3.9; p = 0.016) had shorter OS.
Similarly, DFS was significantly affected by larger tumor size (HR: 1.8; 95% CI = 1.0,
3.2; p = 0.034), presence of necrosis (HR: 1.8; 95% CI = 1.0, 3.1; p = 0.004), vascular invasion
(HR: 2.5; 95% CI = 1.4, 4.2; p = 0.001), ID1 (HR: 2.0; 95% CI = 1.1, 3.6; p = 0.016), and ID4
overexpression (HR: 3.4; 95% CI = 1.9, 6.0; p <0.001). A trend was also observed for HR
negative status (HR: 1.6; 95% CI = 0.9, 2.8; p = 0.080) (Table 2).
We performed Kaplan–Meier curves for OS and DFS (Figure 4) and observed that
patients whose tumors had high levels of ID1 (FC ≥ 2) showed shorter OS (77.0% vs. 85.2%)
and DFS (70.5% vs. 85.2%) rates. However, these differences were only significant for DFS
(p = 0.014). Likewise, tumors with ID4 overexpression presented significantly decreased
rates of OS (69.4 vs. 82.2 ; p = 0.013) and DFS (61.2 vs. 86.3 ; p < 0.001). either ID2
nor I 3 overexpression sho ed significant associations ith S or FS).
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FC < 2 (236) FC ≥ 2 (61)
OR (95% CI) p *
FC < 2 (248) FC ≥ 2 (49)
OR (95% CI) p *% (n) % (n) % (n) % (n)
Age
≥50 188 64.4% (152) 59.0% (36) 0.8 (0.5–1.4) ns 61.3% (152) 73.5% (36) 1.8 (0.9–3.5) ns (0.071)
<50 109 35.6% (84) 41.0% (25) 1 38.7% (96) 26.5% (13) 1
Size
≥20 162 51.3% (121) 68.3% (41) 2.1 (1.1–3.7) 0.012 52.2% (129) 67.3% (33) 1.9 (1.0–3.6) 0.036
<20 134 48.7% (115) 31.7% (19) 1 47.8% (118) 32.7% (16) 1
NA 1
Histological Grade
1 30 11.9% (28) 3.3% (2) 1 11.7% (29) 2.0% (1) 1
2 89 33.1% (78) 18.0% (11) 2.0 (0.4–9.5) ns 32.3% (80) 18.4% (9) 3.3 (0.4–26.9) ns
3 178 55.1% (130) 78.7% (48) 5.2 (1.2–22.5) 0.029 56.0% (139) 79.6% (39) 8.1 (1.1-61.6) 0.042
Necrosis
Present 100 29.9% (70) 50.0% (30) 2.3 (1.3–4.2) 0.003 30.5% (75) 52.1% (25) 2.5 (1.3–4.6) 0.004
Absent 194 70.1% (164) 50.0% (30) 1 69.5% (171) 47.9% (23) 1
NA 3
Vascular Invasion
Present 107 33.8% (79) 45.9% (28) 1.7 (0.9–3.0) ns(0.055) 33.3% (82) 51.0% (25) 2.1 (1.1–3.9) 0.015
Absent 188 66.2% (155) 54.1% (33) 1 66.7% (164) 49.0% (24) 1
NA 2
Lymph Nodes Status
Positive 117 38.1% (90) 44.3% (27) 1.3 (0.7–2.3) ns 37.9% (94) 46.9% (23) 1.5 (0.8–2.7) ns
Negative 180 61.9% (146) 55.7% (34) 1 62.1% (154) 53.1% (26) 1
OR: Odds Ratio; CI: Confidence Interval; NA: not available; ns: not significant (p > 0.05). * Chi-Square Test.
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Table 2. Univariate and multivariate analysis of OS and DFS for all variables included in the study.
Overall Survival Disease-Free Survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR (95% CI) p * HR (95% CI) p * HR (95% CI) p * HR (95% CI) p *
Age
≥50 1.3 (0.7–2.3) ns 0.7 (0.4–1.1) ns
<50 1 1
Size
≥20 2.8 (1.5–5.2) 0.002 1.7 (0.8–3.5) ns 1.8 (1.0–3.2) 0.034 1.3 (0.7–2.4) ns
<20 1 1 1
Histological Grade
1 1 1 1
2 4.2 (0.5–32.9) ns 2.5 (0.3–20.0) ns 1.3 (0.4–3.9) 0.702
3 8.1 (1.1–58.8) 0.040 2.6 (0.3–21.4) ns 2.1 (0.8–5.9) 0.157
Necrosis
Present 1.8 (1.0–3.2) 0.042 1.4 (0.7–2.6) ns 1.8 (1.0–3.1) 0.041 1.8 (1.0–3.1) 0.050
Absent 1 1 1
Vascular Invasion
Present 2.6 (1.4–4.6) 0.001 1.6 (0.8–3.1) ns 2.5 (1.4–4.2) 0.001 1.9 (1.1–3.5) 0.031
Absent 1 1 1
Lymph Nodes
Positive 2.6 (1.4–4.6) 0.001 1.6 (0.8–3.1) ns 1.6 (0.9–2.7) 0.107
Negative 1 1 1
HR Status
Negative 1.8 (1.0–3.3) 0.039 1.3 (0.6–2.4) ns 1.6 (0.9–2.8) ns (0.080)
Positive 1 1 1
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Table 2. Cont.
Overall Survival Disease-Free Survival
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR (95% CI) p * HR (95% CI) p * HR (95% CI) p * HR (95% CI) p *
ID1 FC
≥2 1.3 (0.7–2.5) ns 2.0 (1.1–3.6) 0.016 0.6 (0.3–1.5) ns
<2 1 1
ID2 FC
≥2 0.8 (0.4–1.7) ns 0.9 (0.4–1.7) ns
<2 1 1
ID3 FC
≥2 1.0 (0.5–2.3) ns 0.9 (0.4–1.9) ns
<2 1 1
ID4 FC
≥2 2.1 (1.2–3.9) 0.016 1.6 (0.8–3.0) ns (0.167) 3.4 (1.9–6.0) <0.001 4.0 (1.8–8.9) 0.001
<2 1 1 1
HR, hazard ratio; CI, confidence interval; HR status, hormonal receptor status; ns, not significant (p > 0.05). * Cox model.
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2.6. ID4 Is an Independent Marker of Poor Prognosis in Breast Cancer
All variables that significantly affected OS and DFS were included in Cox’s propor-
tional hazard multivariate analysis (Table 2). Results showed that none of the chosen
factors independently affected OS (all p > 0.05), although a trend towards significance was
observed for ID4 overexpression (p = 0.176). In contrast, the presence of vascular invasion
(p = 0.031), necrosis (p = 0.050), and ID4 overexpression (p = 0.001) were independent
prognostic factors for DFS.
2.7. Comparison with Available Databases
We compared our results with those available in the public database Kaplan Meier
Plotter [45]. Two different cohorts of BC patients were used for these analyses: DFS
(n = 3951) and OS (n = 1402). In agreement with our series, the expression of ID2 and ID3
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did not impact either in DFS or in OS, whereas higher expression of ID1 and ID4 was
associated with poorer DFS (all p < 0.05). Nevertheless, contrary to our data, ID4 did not
significantly correlate with OS for these patients (Figure 4).
3. Discussion
In the current study, we analyzed the presence of the four ID genes in BC and found
that ID4 mRNA expression was higher in BC cell lines than the healthy epithelium control
cells. The expression of the remaining ID genes was also detected in all cell lines studied,
although the expression in BC lines was not significantly higher than in the control model.
In the light of these results, we took the investigation to the next step and studied the
expression of the ID family in 307 non-consecutive samples of human BC stratified by
immunophenotypes. As far as we know, our work represents the largest series where the
mRNA expression of the four ID genes has been simultaneously studied to date.
Our data showed that at least one of these genes was overexpressed in most analyzed
tumor samples compared to healthy breast tissue, supporting their reactivation during
breast carcinogenesis. More concretely, in our series, overexpression of ID1 and ID4
was related to HR-negative immunophenotypes, in contrast to ID2 and ID3, which were
more frequently overexpressed in luminal subtypes. This suggests that each gene could
contribute to the etiopathogenesis of a specific subtype of BC. We further demonstrated
that mRNA overexpression of ID1 and ID4 was linked to aggressive clinicopathological
factors and poorer survival rates. Besides, ID4 showed an independent prognostic value
for recurrence. Our results regarding ID1 are supported by previous studies demonstrating
its expression in HR-negative BC phenotypes [22,46] and implied more aggressive features
and poorer outcomes [22–24,46].
According to our knowledge, the contribution of ID4 in BC aggressiveness is still unclear.
As stated before, in the last decades, the role of ID4 as a tumor suppressor gene has been pro-
posed based on evidence showing an increase in tumor progression and the risk of metastasis
following the loss of ID4 by hypermethylation [40,41]. Nevertheless, opposite data claiming
an increased expression of ID4 in various tumor types have also been reported [37–39]. Along
with this work, we have presented compelling evidence that supports a pro-oncogenic role
of this gene in BC progression. Our in vitro data demonstrates that the expression of ID4 is
higher in tumor cell lines than in healthy breast epithelium.
Moreover, our study in a large series of BC patients establishes an association between
ID4 overexpression and aggressive clinic-pathological features and BC subtypes. Addi-
tionally, ID4 showed an independent prognostic value for recurrence. Comparably, other
authors have studied ID4 expression at the protein level in BC specimens and found corre-
lations with high tumor grade, absence of HR, increased vascularization and recurrence,
and shorter OS [47–52]. The expression of ID4 has also been linked to a stem-like pheno-
type in the aggressive basal-like BC subtype [53]. In agreement, our work demonstrated
that these associations are also found at the mRNA level. These data together support
the involvement of ID4 in the pathogenesis of BC beyond the dysregulation of BRCA1
expression. A very recent work carried out on a short series of basal-like BC samples
and cell lines showed that the interaction between ID4 and DNA damage repair proteins
could contribute to the DNA damage repair deficiencies and the aggressiveness of this BC
subtype [54]. These data support the high association between ID4 overexpression and the
most aggressive BC phenotypes in our series.
Unfortunately, the current work did not contribute to elucidating the role of ID2 and
ID3 in BC. Previous reports aimed at studying both genes in BC, and their conclusions
were divergent [24,26,29]. Considering the above data and our results, it seems that these
two genes have a secondary role in BC progression. Nevertheless, further research could
be carried out to elucidate these discrepancies.
Interestingly, other authors have found opposite conclusions about ID1 and ID4
mRNA expression in BC. Zhou and colleagues recently evaluated the prognostic relevance
of the ID family by using a set of public databases and reported that higher mRNA levels
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of ID1 and ID4 were associated with lower histological grades, less lymph-node metastasis,
and longer survival rates [25]. As our results differ from those presented by Zhou et al. [25],
we carried out a prognosis analysis with the data available at the database Kaplan–Meier
Plotter. In agreement with our results, Kaplan–Meier Plotter data showed that high mRNA
levels of ID1 and ID4 correlated with shorter DFS rates. In contrast, the overexpression of
ID2 or ID3 showed no association with survival.
The discordances found between ID1 expression in cell lines and patient samples
could be explained considering the nature of this gene. It is known that ID1 acts as a
driver of cell proliferation, and all the cell lines in our in vitro study are highly proliferative.
Consequently, all studied cell lines, including the non-tumor cell line 184A1, presented
high rates of ID1 expression. This fact has previously been reported [55] and suggests
that interactions between tumor and stromal cells may regulate IDs expression [56], which
is an interesting field for further research, especially in the different subtypes of BC.
Other in vitro studies have demonstrated that induced expression of ID1 transformed
non-aggressive BC cell lines into more aggressive cells [21,26]. That is in agreement with
our data since the less aggressive luminal cell lines, T47-D, showed reduced levels of ID1
compared to the invasive TNBC MDA-MB-231 and MDA-MB-468.
In conclusion, our results support that ID1 and ID4 have a role as pro-oncogenes
in BC and are associated with tumor aggressiveness in BC subtypes. In addition, they
seem relevant molecular prognostic markers in this neoplasia. Our findings of ID4 are
especially interesting, considering the increasing controversy about the role of this gene
in BC. Therefore, both genes seem potential targets for developing novel drugs for BC
treatment, specifically in more aggressive phenotypes such as TNBC and HER2-enriched.
Of note, this strategy is now more realistic considering that Wojnarowicz and colleagues
have recently developed a molecule that successfully targets and disrupts ID proteins
in vitro and in vivo [57]. Nevertheless, our results, which have potential therapeutic
implications, warrant further investigation.
4. Materials and Methods
4.1. Cell Culture
Six human BC cell lines: MCF-7 and T47-D (luminal A-like), BT474 (luminal B/HER2-
negative), SKBR3 (HER2-enriched), MDA-MB-231, and MDA-MD-468 (TNBC), and the
normal breast epithelium cell line (184A1) were purchased from ATCC (Manassas, VA,
USA). All tumor cell lines were maintained in 75 cm2 flask (SPL Life Science, Gyeonggi,
Korea) fed with Dulbecco Modified Eagle Medium/Ham F12 (1:1) with L-glutamine and 15
mM HEPES media (Biowest, Nauaillé, France) supplemented with 10% Fetal Bovine Serum
(Biowest, Nauaillé, France), 50 U/mL penicillin and 50 mg/mL streptomycin (Biowest,
Nauaillé, France). The cell line 184A1 was maintained in Mammary Epithelial Cell Growth
Medium (MEGM BullekitTM Lonza, Basel, Switzerland) supplemented with growth factors
(MEGMTM SingleQuotsTM Supplements, Lonza, Basel, Switzerland), and 1% penicillin and
streptomycin (Biowest, Nauaillé, France). Cells were incubated in humidified incubators at
37 ◦C and 5% CO2.
Once a year, or when cells were thawed out, a mycoplasma test was carried out follow-
ing the instructions of the Venor®GeM One Step kit (Minerva BioLabs, Berlin, Germany).
Cells were maintained in culture for a few weeks, enough time for a couple of passages,
and needed experiments.
4.2. Patients
Our retrospective study included 307 non-consecutive samples from patients with
primary BC diagnosed and treated at the University General Hospital of Alicante (Spain)
between 1993 and 2016. Tumor specimens were obtained from the Biobank collections of
the same institution. Inclusion criteria were: diagnosis of resectable infiltrative primary
breast carcinoma of at least 10 mm in size, stage I-III, complete pathological report, and
those patients who had not been lost to follow-up in at least 12 months. Patients with
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tumors in stage IV, with preoperative chemo-/radiotherapy or low quality/quantity of
RNA, were excluded from the study. The Local Ethics Committee approval was obtained
for this project (ethic code PI2014/39), informed consent from all individual participants
were collected, and patients’ data were anonymized. This study was conducted following
the Declaration of Helsinki and has been written following the REMARK criteria [58].
The studied variables were age, tumor size, histological grade (Scarff–Bloom–Richardson
classification modified by Elston and Ellis), vascular invasion, necrosis, nodal status, and
immunophenotype. Survival data were obtained from clinical reports. Overall survival
(OS) was defined as the period between surgery and patient’s death, and disease-free
survival (DFS) as the time between surgery and recurrence.
Patients were treated either with breast-conserving surgery or mastectomy. Post-
lumpectomy radiotherapy was given at a total dose of 50 Gy after surgery, and those
patients with HR-positive tumors were additionally treated with tamoxifen/aromatase in-
hibitors for 2–5 years. High-risk patients (young age, high histological grade, HR-negative
tumors, or positive lymph nodes) received systemic chemotherapy after surgery, with 6
cycles of cyclophosphamide, methotrexate, 5-fluorouracil, or four cycles of doxorubicin
plus cyclophosphamide. In our institution, trastuzumab (HerceptinTM) was approved to
be added to chemotherapy protocols in HER2-positive BC patients after 2005.
4.3. Immunohistochemistry (IHC) and FISH
Tissue microarrays (TMAs), including two cores of 1 mm from each formalin-fixed
paraffin-embedded (FFPE) tumor, were made (Beecher Instruments) and stained with im-
munohistochemical standard techniques at conditions detailed in Supplementary Materials
(Table S4). Two independent pathologists analyzed the results. Positive scores for staining
were set as follows: HR (ER and PR) >1% (nuclei), Bcl2 > 50% (cytoplasm), p53 > 20%
(nuclei), Ki67 ≥ 14% (nuclei), any degree of CK5/6 (cytoplasmic) or EGFR (membrane) [59]
and HER2 according to the 2018 scoring guidelines (>10%, 3+cells). HER2 equivocal cases
(2+ and <10% 3+) were confirmed by FISH (HER2 IQFISH pharmaDxTM; Agilent Technolo-
gies/Dako; Carpinteria, CA, USA) [60,61]. According to the St Gallen recommendation,
intrinsic subtypes were classified based on the IHC results [62].
4.4. RNA Isolation and cDNA Synthesis
Two punches (1 mm thick/≥4 mm deep) of FFPE tissue from preselected areas were
used for RNA isolation. Samples were first deparaffinized by grinding them into small
pieces and incubating them with mineral oil (Sigma-Aldrich, Steinheim, Germany) at high
temperature (95 ◦C). RNA isolation was carried out in the robotic workstation QIAcube
(QIAGEN, Hilden, Germany) following the instructions of the RNeasy FFPE Kit (QIAGEN,
Hilden, Germany) for tissue samples and RNeasy Minikit (QIAGEN, Hilden, Germany) for
cell culture samples. A step of incubation with DNase (QIAGEN, Hilden, Germany) was
included to eliminate any genomic DNA contamination. The final RNA concentration and
purity were measured with a NanoDrop spectrophotometer (Thermo Scientific, Waltham
MA, USA). For the reverse transcription reaction, 1.5 µg of RNA was used as a template
in a total volume of 20 µL according to recommendations of the High-Capacity cDNA
Reverse Transcription Kit (Thermo Fischer Scientific, Waltham MA, USA).
4.5. Quantitative Real-Time PCR (qRT-PCR)
The qRT-PCR was carried out in a Real-Time PCR System 7500-FAST (Applied Biosys-
tems, Foster City, CA, USA) using the TaqMan® Fast Universal PCR Master Mix and
TaqMan® Gene Expression Assays (Life Technologies, CA, USA) containing specific exon-
junction probes: PUM1 (Hs00472881_m1), β-ACTIN (Hs01060665_g1), ID1 (Hs03676575_s1),
ID2 (Hs04187239_m1), ID3 (Hs00171409_m1) and ID4 (Hs02912975_g1). Since ID1 contains
only one exon, we performed control reactions to ensure that the selected assay does
not amplify genomic DNA. The qRT-PCR reaction took place in a total volume of 10 µl
according to the manufacturers’ instructions. PUM1 and β-ACTIN were used as reference
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genes. All reactions were done in duplicates, and no-template controls were included in
each plate. Relative changes in mRNA expression were calculated as the fold change (FC)
by the 2-∆∆Ct method using as reference sample a pool of breast epithelium tissues from 10
healthy patients who underwent a breast reduction in the case of tissue samples, or the cell
line 184A1 for BC cell lines. Tumor samples showing double expression than the control
(FC ≥ 2) were considered overexpressed. Results were analyzed with the 7500 Software
v2.06 (Applied Biosystems, Foster City, CA, USA).
4.6. Statistical Analyses
The Kolmogorov–Smirnov test was used to identify whether variables were normally
distributed. Parametric variables were defined by the average ± standard deviation,
non-parametric variables were by the median and 25–75th percentiles or mean and range
(min-max), and qualitative variables were defined by the frequency percentage of each
subgroup. The Chi-square test was used to measure associations between qualitative
variables. Log-rank tests were used for the comparison of Kaplan–Meier survival curves.
Univariate and multivariate survival analyses were performed using the Cox proportional
hazard model. All molecular and clinicopathological variables having a P-value < 0.05 in
the univariate analyses were considered for the multivariate analyses. For the purpose of
the study, samples were classified according to the expression FC as normal-low expression
(FC < 2) versus overexpression (FC ≥ 2).
In cell culture experiments, expression was defined as the average and standard
deviation among replicates. Differences in expression among cell lines were compared
with the Student’s T-test. p-values < 0.05 were regarded as statistically significant, whereas
those between 0.05–0.10 were considered marginally significant. All statistical analyses
were conducted using SPSS version 22.0 (SPSS Inc, Chicago, IL, USA).
5. Conclusions
ID4, which is the ID family member that differs the most in terms of sequence and
function, is highly expressed in breast cancer cell lines than breast healthy tissue cell
line. In breast cancer biopsies, ID4 and ID1 are overexpressed in a subset of samples that
predominantly presented more aggressive phenotypes and shorter overall and disease-free
survival. These results have been previously suggested for ID1, but there was not enough
evidence showing a pro-oncogenic role of ID4 in breast cancer.
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